| G09 Stock | | | EUR 707.37 3.80 0.53% |
CFO
Pierre Schwich is Chief Financial Officer of Genomic Vision Socit since 2020.
| Age | 70 |
| Tenure | 4 years |
| Phone | 33 1 49 08 07 40 |
| Web | https://www.genomicvision.com |
Genomic Vision Management Efficiency
The company has return on total asset
(ROA) of
(0.494) % which means that it has lost $0.494 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(2.4593) %, meaning that it generated substantial loss on money invested by shareholders. Genomic Vision's management efficiency ratios could be used to measure how well Genomic Vision manages its routine affairs as well as how well it operates its assets and liabilities.
Genomic Vision Socit has accumulated 816
K in total debt with debt to equity ratio
(D/E) of 0.28, which may suggest the company is not taking enough advantage from borrowing. Genomic Vision Socit has a current ratio of 2.04, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Genomic Vision until it has trouble settling it off, either with new capital or with free cash flow. So, Genomic Vision's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Genomic Vision Socit sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Genomic to invest in growth at high rates of return. When we think about Genomic Vision's use of debt, we should always consider it together with cash and equity.
Genomic Vision Socit Anonyme, a molecular diagnostics and technology company, engages in the development of single DNA detection tools for research and in vitro diagnostics in France. The company was founded in 2004 and is headquartered in Bagneux, France. GENOMIC VISION operates under Diagnostics Research classification in Germany and is traded on Frankfurt Stock Exchange. It employs 27 people. Genomic Vision Socit (G09) is traded on Frankfurt Exchange in Germany and employs 33 people.
Management Performance
Genomic Vision Socit Leadership Team
Elected by the shareholders, the Genomic Vision's board of directors comprises two types of representatives: Genomic Vision inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genomic. The board's role is to monitor Genomic Vision's management team and ensure that shareholders' interests are well served. Genomic Vision's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genomic Vision's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Emilie Chataignier, Member Board | |
| Beth Jacobs, Independent Member of the Supervisory Board | |
| Pierre Schwich, Chief Financial Officer | |
| Isabelle Racamier, Independent Chairman of the Supervisory Board | |
| Tamar Saraga, Independent Member of the Supervisory Board | |
| Stephane Verdood, Member of the Supervisory Board | |
| Elisabeth Ourliac, Independent Vice Chairwoman of the Supervisory Board | |
| Stephane Altaba, Vice President - Corporate Development, Member of the Management Board | |
| Mark Lynch, Global Director | |
| Jerome Vailland, Chief Financial Officer | |
| Aaron Bensimon, Chairman of the Management Board, Chief Scientific Officer | |
Genomic Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Genomic Vision a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in Genomic Stock
Genomic Vision financial ratios help investors to determine whether Genomic Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Genomic with respect to the benefits of owning Genomic Vision security.